Whistler Medical Marijuana Corporation has released Canada’s first high cannabigerol (CBG) oil following two years of research and development, the company announced in a press release. While the non-psychoactive compound is not as well studied as THC or CBD, research suggests it is a useful therapy to combat inflammation, nausea, and pain, and slows the proliferation of cancer cells.
“Basic research has indicated that CBG exerts a variety of effects in cell culture and animal models including acting as an anti-inflammatory, analgesic and anti-fungal,” Brishna Kamal, WMMC’s director of medical research, said in the release. “It is currently being investigated for a possible treatment for many disorders including cancer, glaucoma, inflammatory bowel disease, different types of pain, and even neurodegenerative diseases such as Huntington’s.”
The oil contains both CBG and THC in a 3-to-2 ratio and will be released exclusively to patients registered with the company in order to help them determine which conditions are effectively treated by the product.
Daniel Lantela, chief science officer and creator of the cannabis oil program, said the company’s products attempt to retain the “entourage effect” and they are “dedicated to unlocking the full potential of the cannabis plant for all patients in medicinal need.”
The high-CBG offering is the first of its kind in the country.
Get daily cannabis business news updates. Subscribe